Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07117383) titled 'Hezkue(R), Hezkue Turbo(R), and Commercial Sildenafil Products in Fed Healthy Male Subject' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Aspargo Labs, Inc
Condition:
Erectile Dysfunction
Intervention:
Device: ASP-001.1
Drug: ASP-001
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 2025
Target Sample Size: 72
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07117383
Published...